tirzepatide heart failure fda What Is Used for? Approved and Potential Uses FDA approves tirzepatide, Eli Lilly's

Data from the Business Group on Health show 67% of large employers cover GLP-1s in 2026

Hepatology: Rare Stevens-Johnson syndrome and vanishing bile duct syndrome induced by acetaminophen, requiring liver transplantation

Medical Writing/Editorial Assistance The authors would like to thank Karen Nunley, PhD (Syneos Health) for medical writing assistance, and Raena Fernandes, MSc, ELS and Aruna Clemente, PhD, (both of Syneos Health) for editorial assistance

Broader utility drives market dominance: GLP1s address not only diabetes and obesity, but also cardiovascular and other metabolic comorbidities, creating opportunities to position them as multicondition solutions